ProCE Banner Activity

Interpreting COVID-19 Data From IDWeek 2022: Prophylaxis, Treatment, and Opportunistic Infections in Immunocompromised Individuals

Clinical Thought

COVID-19 continued to be a major focus at IDWeek 2022, with research investigating many facets of infection, including 4 studies that I found particularly interesting—analyses of baricitinib or tocilizumab for severe COVID-19, inhaled interferon beta-1a for moderate COVID-19, and tixagevimab plus cilgavimab for pre-exposure prophylaxis in immunocompromised individuals, and outcomes among adult solid organ transplant recipients with COVID-19–associated fungal infections.

Released: November 17, 2022

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Cristina Mussini, MD

Full Professor of Infectious Diseases
Division of Infectious Diseases
University of Modena and Reggio Emilia
Modena, Italy

Cristina Mussini, MD: consultant/advisor/speaker: AbbVie, Angelini, Gilead Sciences, GlaxoSmithKline, Janssen, MSD, Pfizer, Roche, ViiV Healthcare; researcher: Gilead Sciences, Janssen, MSD, ViiV Healthcare.